Cargando…

Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018

BACKGROUND: Antipsychotic prescribing to Medicaid-enrolled youth has been the target of numerous policy initiatives, including prior authorization and quality monitoring programs, which often target specific populations. Whether these efforts have changed the level or composition of antipsychotic pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Candon, Molly, Shen, Siyuan, Fadeyibi, Oluwatoyin, Smith, Joseph L, Rothbard, Aileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540198/
https://www.ncbi.nlm.nih.gov/pubmed/34686159
http://dx.doi.org/10.1186/s12888-021-03533-3
_version_ 1784588928982974464
author Candon, Molly
Shen, Siyuan
Fadeyibi, Oluwatoyin
Smith, Joseph L
Rothbard, Aileen
author_facet Candon, Molly
Shen, Siyuan
Fadeyibi, Oluwatoyin
Smith, Joseph L
Rothbard, Aileen
author_sort Candon, Molly
collection PubMed
description BACKGROUND: Antipsychotic prescribing to Medicaid-enrolled youth has been the target of numerous policy initiatives, including prior authorization and quality monitoring programs, which often target specific populations. Whether these efforts have changed the level or composition of antipsychotic prescribing is unclear. METHODS: Using 2014–2018 administrative claims data for Medicaid enrollees aged 21 years and under in Philadelphia, Pennsylvania, we measured antipsychotic prescription fills overall and for youth without an approved indication (autism, bipolar disorder, or psychosis). We then assessed whether trends differed for populations that have been targeted by policy initiatives, including younger children and foster care-enrolled youth. We also identified the most common approved and unapproved indications and examined whether the treatment duration of antipsychotic prescriptions differed based on whether the youth had an approved or unapproved indication. RESULTS: Overall, the number of Medicaid youth with an antipsychotic prescription fill halved between 2014 and 2018. Youth aged 17 years and under and foster care-enrolled youth, who were targeted by prior authorization and quality improvement efforts, experienced larger declines. Roughly half of prescriptions were for unapproved indications in both 2014 and 2018; the most common unapproved indication was ADHD, and the treatment duration was shorter for unapproved indications compared to approved indications. CONCLUSIONS: Antipsychotic prescribing to Medicaid-enrolled youth is declining, particularly among populations that have been targeted by policy initiatives like prior authorization and quality monitoring programs. Despite the fact that these initiatives often assess diagnostic criteria, half of antipsychotic prescriptions were for unapproved indications in both 2014 and 2018. More research is needed to gauge whether this prescribing is appropriate.
format Online
Article
Text
id pubmed-8540198
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85401982021-10-25 Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018 Candon, Molly Shen, Siyuan Fadeyibi, Oluwatoyin Smith, Joseph L Rothbard, Aileen BMC Psychiatry Research BACKGROUND: Antipsychotic prescribing to Medicaid-enrolled youth has been the target of numerous policy initiatives, including prior authorization and quality monitoring programs, which often target specific populations. Whether these efforts have changed the level or composition of antipsychotic prescribing is unclear. METHODS: Using 2014–2018 administrative claims data for Medicaid enrollees aged 21 years and under in Philadelphia, Pennsylvania, we measured antipsychotic prescription fills overall and for youth without an approved indication (autism, bipolar disorder, or psychosis). We then assessed whether trends differed for populations that have been targeted by policy initiatives, including younger children and foster care-enrolled youth. We also identified the most common approved and unapproved indications and examined whether the treatment duration of antipsychotic prescriptions differed based on whether the youth had an approved or unapproved indication. RESULTS: Overall, the number of Medicaid youth with an antipsychotic prescription fill halved between 2014 and 2018. Youth aged 17 years and under and foster care-enrolled youth, who were targeted by prior authorization and quality improvement efforts, experienced larger declines. Roughly half of prescriptions were for unapproved indications in both 2014 and 2018; the most common unapproved indication was ADHD, and the treatment duration was shorter for unapproved indications compared to approved indications. CONCLUSIONS: Antipsychotic prescribing to Medicaid-enrolled youth is declining, particularly among populations that have been targeted by policy initiatives like prior authorization and quality monitoring programs. Despite the fact that these initiatives often assess diagnostic criteria, half of antipsychotic prescriptions were for unapproved indications in both 2014 and 2018. More research is needed to gauge whether this prescribing is appropriate. BioMed Central 2021-10-22 /pmc/articles/PMC8540198/ /pubmed/34686159 http://dx.doi.org/10.1186/s12888-021-03533-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Candon, Molly
Shen, Siyuan
Fadeyibi, Oluwatoyin
Smith, Joseph L
Rothbard, Aileen
Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title_full Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title_fullStr Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title_full_unstemmed Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title_short Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018
title_sort trends in antipsychotic prescribing for approved and unapproved indications to medicaid-enrolled youth in philadelphia, pennsylvania between 2014 and 2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540198/
https://www.ncbi.nlm.nih.gov/pubmed/34686159
http://dx.doi.org/10.1186/s12888-021-03533-3
work_keys_str_mv AT candonmolly trendsinantipsychoticprescribingforapprovedandunapprovedindicationstomedicaidenrolledyouthinphiladelphiapennsylvaniabetween2014and2018
AT shensiyuan trendsinantipsychoticprescribingforapprovedandunapprovedindicationstomedicaidenrolledyouthinphiladelphiapennsylvaniabetween2014and2018
AT fadeyibioluwatoyin trendsinantipsychoticprescribingforapprovedandunapprovedindicationstomedicaidenrolledyouthinphiladelphiapennsylvaniabetween2014and2018
AT smithjosephl trendsinantipsychoticprescribingforapprovedandunapprovedindicationstomedicaidenrolledyouthinphiladelphiapennsylvaniabetween2014and2018
AT rothbardaileen trendsinantipsychoticprescribingforapprovedandunapprovedindicationstomedicaidenrolledyouthinphiladelphiapennsylvaniabetween2014and2018